poisar

Stock

SGMO SGMO

$0.18+0.00%

Overview

SGMO market data

Price History

SGMO price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$0.44
Diluted earnings per share over the trailing twelve months.
Beta
1.43
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$0.03 – $0.77
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $28.2 · P/B 9.35 · P/S 0.82.

Company News

7 captured
Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas CircleBenzinga · Jun 23, 2026, 5:50 PM
Sangamo Therapeutics Files For Chapter 11 Bankruptcy, Secures Up To $30M In Debtor-In-Possession Financing; Launches Court-Supervised Asset Sale Process With Eli Lilly And Astellas As Stalking Horse Bidders For Key Gene Therapy, Genome Editing, And Fabry Disease Assets; Expects Restructuring To Result In Elimination Of About 51 Roles In U.S., Or About 40% Of Company's WorkforceBenzinga · Jun 23, 2026, 1:01 PM
8-K filing — SANGAMO THERAPEUTICS, INC (SGMO)SEC EDGAR · Jun 23, 2026, 12:45 PM
Deal Dispatch: Carlyle Buys Chung Ho Group, Second Nature Brands Acquires Tillamook Country Smoker, GoHealth BankruptcyBenzinga · Jun 12, 2026, 7:15 PM
Full Transcript: Sangamo Therapeutics Q1 2026 Earnings CallBenzinga · May 14, 2026, 9:00 PM
Sangamo Therapeutics Q1 EPS $(0.08) Misses $0.01 Estimate, Sales $1.442M Miss $33.725M EstimateBenzinga · May 14, 2026, 8:05 PM
Earnings Scheduled For May 14, 2026Benzinga · May 14, 2026, 11:11 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock